Success Stories: A Postdoctoral Associate in the Field of Molecular Biology Secured NIW Approval with Our Honed Petition Packet

Client’s Testimonial:

“I highly appreciate Wegreen team’s help on getting my NIW petition approved. They offered clear and prompt responses all the time. I would recommend the firm to whomever need the same service.”

On March 24^th, 2021, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Associate in the Field of Molecular Biology (Approval Notice).

General Field: Molecular Biology

Position at the Time of Case Filing: Postdoctoral Associate

Country of Origin: China

State of Residence at the Time of Filing: Maryland

Approval Notice Date: March 24^th, 2021

Processing Time: 9 months, 15 days

Case Summary:

An EB-2 NIW (National Interest Waiver) petition approval was granted to a postdoctoral associate from China. Before commencing the attorney-client relationship with her, we thoroughly assessed her credentials to verify the authenticity. After a complete evaluation, we affirmed that we could help her obtain the national interest waiver. Our team gathered all the relevant key points to be emphasized in her petition packet confirming her academic and professional attainments. Here are some of the following details:

Primarily, we noted that she held a Ph.D. in immunology and microbiology with extensive experience researching the field of molecular biology. Also, that she had published 3 peer-reviewed journal articles (2 of them first-authored), which altogether amassed 75 citations, concluding that she has a major influence on other scholars in the field. Besides, she conducted 2 peer reviews for highly acclaimed journals to date. This indicates the significance and impact of her investigations and vast knowledge in this area of study.
More importantly, we briefed her research focused on investigating HIV infection and host immune response by determining the underlying molecular pathways involved in HIV latency for the enhanced development of antiretroviral drugs, flu vaccines, and the eradication of HIV. Our sole aim was to determine that her research is of great importance as it cures disease and protects public health. It seemed to be directly relevant to national health goals.
Furthermore, we added that her research has been supported by funding grants from leading agencies, another measure of her success in pursuing her work here in the U.S. This funding includes grants from the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH), the National Basic Research Program of China, and the National Natural Science Foundation of China (NSFC), therefore demonstrates the significance and national importance of her research. To corroborate further, we incorporated 5 recommendation letters gathered from her peers, and according to one of them:

“[Client’s] work serves those in the U.S. on account of HIV’s continued presence in the country… Obviously, studying HIV progression, prevention, and treatment is inherently worthwhile. With no cure for HIV yet, her work embodies a breakthrough. In this way, her research concerns all Americans, not just those with HIV.”

Overall, we proved to the USCIS that our client should be allowed to continue her research in the U.S. as she offers contributions of such value that, on the whole, they would benefit the United States. Thus, USCIS took the time to adjudicate her case wisely and granted the NIW approval. Our team at the North America Immigration Law Group thanks our client for associating with us and allowing us to be a part of her triumph.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.